In this article from Pharmaceutical Outsourcing, John McDermott, Vice President of Scientific Consulting at Quotient Sciences, talks about the evolving landscape of oral solid dosage (OSD) manufacturing.
While 3D screen printing is revolutionizing drug formulation with its precision and customization, John emphasizes the continued relevance of batch manufacturing.
John also talks about the increasing industry focus towards rare and orphan diseases and highlights the importance of small, agile CDMOs and a balanced approach to technology adoption to meet the diverse demands of modern drug development.
Speaking about trends that are driving the growth of the OSD contract manufacturing market, John notes: "Controlled-release formulations can provide an option for a more effective treatment and better patient compliance and offer an ideal life-cycle management solution. Careful development and control of these formulations is necessary to ensure the optimal pharmacokinetic profile is achieved."
Read the full article on the Pharmaceutical Outsourcing.
"Controlled-release formulations can provide an option for a more effective treatment and better patient compliance and offer an ideal life-cycle management solution."
-John McDermott